Device
Conventional RT
Conventional RT is a medical device with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 33.3%.
Total Trials
5
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
1(20%)
Results Posted
100%(1 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_1
1
20%
Ph phase_3
1
20%
Ph not_applicable
3
60%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
3(60.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(1)
Terminated(2)
Other(1)
Detailed Status
Terminated2
Completed1
unknown1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
33.3%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (20.0%)
Phase 31 (20.0%)
N/A3 (60.0%)
Trials by Status
completed120%
terminated240%
unknown120%
active_not_recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
active_not_recruitingnot_applicable
FLASH Radiotherapy for Skin Cancer
NCT05724875
completedphase_3
Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma
NCT03722355
terminatedphase_1
Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer
NCT01222572
terminatednot_applicable
Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0)
NCT00563862
unknownnot_applicable
Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)
NCT00563927
Clinical Trials (5)
Showing 5 of 5 trials
NCT05724875Not Applicable
FLASH Radiotherapy for Skin Cancer
NCT03722355Phase 3
Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma
NCT01222572Phase 1
Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer
NCT00563862Not Applicable
Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0)
NCT00563927Not Applicable
Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)
All 5 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 5